Plasma proprotein‐convertase‐subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes

• DOI: 10.1111/dom.13181
• Publication Date: 2017-12-05T13:38:51Z
• Authors: Petra El Khoury; Ronan Roussel; Frederic Fumeron; Yara Abou‐Khalil; Gilberto Velho; Kamel Mohammedi; Marie‐Paule Jacob; Philippe Gabriel ...; Louis Potier; Youmna Ghaleb; Sandy Elbitar; Stephanie Ragot; Francesco Andreata; Giusepinna Caligiuri; Samy Hadjadj; Catherine Boileau; Michel Marre; Marianne Abifadel; Mathilde Varret; Boris Hansel
• Keywords: PCSK9; Stroke; Kexin; Clinical endpoint

Aim To investigate whether plasma concentrations of proprotein‐convertase‐subtilisin/kexin type 9 (PCSK9) were associated with cardiovascular (CV) events in two cohorts patients 2 diabetes mellitus. Methods We considered from the DIABHYCAR ( n = 3137) and SURDIAGENE 1468) studies. Baseline PCSK9 concentration was measured using an immunofluorescence assay. In post hoc, but preplanned, analyses we assessed relationship between following endpoints: (1) a combined endpoint major CV events: death, non‐fatal myocardial infarction (MI), stroke heart failure‐related hospital admission; (2) composite all MI, stroke, admission, coronary/peripheral angioplasty or bypass, death; (3) MI; (4) stroke/transient ischaemic attack (TIA); (5) death. Results study, tertiles incidence stroke/TIA P for trend <.05). adjusted Cox analysis, associated, independently classic risk factors, (hazard ratio [HR] 1‐unit increase log[PCSK9] 1.28 [95% confidence interval {CI} 1.06‐1.55]), MI (HR 1.66 CI 1.05‐2.63]), 1.22 1.04‐1.44]), not Plasma disease participants study high treated statins insulin. Conclusions found that inconsistently populations diabetes. The association may depend on level background treatment.